the Department of Family Medicine, University of South Florida, Tampa, FL; the H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; the Department of Family Medicine and Community Health, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, NJ; the Cancer Institute of New Jersey, Trenton, NJ; and the Division of General Medicine and Primary Care, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
J Am Board Fam Med. 2013 Nov-Dec;26(6):637-47. doi: 10.3122/jabfm.2013.06.130042.
Ambulatory visits to dermatologists and primary care physicians (PCPs) may improve melanoma outcomes through early detection. We sought to measure the effect of dermatologist and PCP visits on melanoma stage at diagnosis and mortality.
We used data from the database linking Surveillance Epidemiology and End Results (SEER) and Medicare data (1994 to 2005) to examine patterns of dermatologist and PCP ambulatory visits before diagnosis for 18,884 Medicare beneficiaries with invasive melanoma or unknown stage at diagnosis. Visits were assessed during the 2-year time interval before the month of diagnosis. We examined whether dermatologist and PCP visits were associated with diagnosis of thinner melanomas (defined as local stage tumors having Breslow thickness <1 mm) and lower melanoma mortality.
Medicare beneficiaries visiting both a dermatologist and PCP before diagnosis had greater odds of diagnosis of a thin melanoma (adjusted odds ratio, 1.26; 95% confidence interval, 1.12-1.41) and lower melanoma mortality (adjusted hazard ratio 0.66, 95% confidence interval, 0.57-0.76) compared with those without such visits. The mortality findings were attenuated once stage at diagnosis was adjusted for in the multivariable model.
Improved melanoma outcomes among Medicare beneficiaries may depend on adequate access and use of dermatologist and PCP services.
皮肤科医生和初级保健医生(PCP)的门诊就诊可能通过早期发现来改善黑色素瘤的预后。我们旨在衡量皮肤科医生和 PCP 就诊对诊断时黑色素瘤分期和死亡率的影响。
我们使用了从监测流行病学和最终结果(SEER)数据库链接到医疗保险数据(1994 年至 2005 年)的数据,以检查 18884 名患有浸润性黑色素瘤或诊断时未知分期的医疗保险受益人的皮肤科医生和 PCP 门诊就诊模式。就诊情况在诊断前的 2 年时间间隔内进行评估。我们检查了皮肤科医生和 PCP 就诊是否与诊断出较薄的黑色素瘤(定义为 Breslow 厚度<1 毫米的局部阶段肿瘤)和较低的黑色素瘤死亡率相关。
与未进行此类就诊的患者相比,在诊断前同时看皮肤科医生和 PCP 的医疗保险受益人诊断出薄型黑色素瘤的可能性更高(调整后的优势比,1.26;95%置信区间,1.12-1.41),且黑色素瘤死亡率更低(调整后的危险比 0.66,95%置信区间,0.57-0.76)。一旦在多变量模型中根据诊断时的分期进行调整,死亡率的发现就会减弱。
医疗保险受益人的黑色素瘤预后改善可能取决于充分获得和利用皮肤科医生和 PCP 服务。